24 Jun, 2024 Clarivate for Life Sciences & Healthcare highlights Tallac Therapeutics as one of the seven Companies to Watch that are revolutionizing antibody drug conjugates (ADCs).
10 Apr, 2024 Tallac Therapeutics Presents New Preclinical Data on TAC-001 in Combination with Cancer Vaccines at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
27 Sep, 2023 Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
11 Nov, 2022 Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
28 Jul, 2022 Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
19 May, 2022 Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
4 Mar, 2021 ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
1 Dec, 2020 Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
